SA EMS ROAD EXPERIENCE • HPCSA STATUTORY DRUG MONOGRAPH
FENOTEROL
Fenoterol Hydrobromide (Berotec)
HPCSA CDST 2024 (Version 1.3 Framework)
Official Statutory Clinical Reference
Short-Acting Beta-2 Adrenergic Agonist (SABA) • BronchodilatorHPCSA CDST 2024 (v1.3 Framework)
•
FENOTEROL
Fenoterol Hydrobromide (Berotec)
Clinical Summary: A rapid-acting, short-acting Beta-2 adrenergic receptor agonist (SABA) delivering potent bronchodilation and relief of acute bronchospasm in asthma and COPD.
Authorized HPCSA Emergency Care Scope of Practice (Annexure A 2022)Statutory Board Mandate
LEGENDARY BAA (PLAIN TEXT - NO COLOR)ECA (*)AEA (*)ECT (*)LEGENDARY CCA (^) [ANT PARAMEDIC]NDIP EMC (^) [ANT PARAMEDIC]ECP ONLY (~)
FENOTEROL Audio BriefingCLINICAL PROFESSOR
No Audio Published Yet
00:00Full Monograph
1. Mechanism of Action
How this drug operates physiologically in the human body
2. Statutory Clinical Indications
1 UsesStrictly per HPCSA CDST v1.3, Annexure A & CPG
3. Adverse Effects & Pathophysiology
Why the body reacts and why it occurs in specific indications
4. Contraindications & Lethal Risks
Biological consequences & why it threatens life
5. Statutory Resources & Quotes
Verbatim regulatory excerpts with deep external links
SA EMS FIELD PROTOCOLS • EDUCATIONAL REVIEW & STATUTORY CITATIONS
An independent educational review and study companion based on the official HPCSA CDST 2024 (Version 1.3 Framework), CPG 2018, and Annexure A (2022) sourced directly from the official HPCSA publication portal. Not for live on-scene patient management.
Author: Jacoline (Jax) Geldenhuys, BEMC • HPCSA Registered Emergency Care Practitioner (ECP)